Lannett will be the First Pharma Company to go Bankrupt amid Continuing Drug Pricing Scrutiny
If Even Modest Price Cuts Hit Either of Lannett’s Cash Cow Drugs, It Will Violate Its Debt Covenants
$13-$15 Near Term Target
Equity Worthless Over Long-Term
In the past month we have seen a series of lawsuits against Lannett that Wall Street has completely overlooked. These lawsuits, along with the Trump administration’s dedication to confront indiscriminate drug price raises, illuminates a clear path to 0 for the equity of Lannett.
/wp-content/uploads/2017/01/lannett-header.jpg513867Citron Research/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.pngCitron Research2017-01-17 08:40:572017-05-29 05:05:35Lannett: Citron Exposes the Lawsuits that will Wipe Out the Equity